Thursday, November 5, the british pharmaceutical giant, AstraZeneca, expects its vaccine data to be available by year-end.
According to the pharmaceutical giant, “Results from late-stage trials are anticipated later this year, depending on the rate of infection within the communities where the clinical trials are being conducted. Data readouts will be submitted to regulators and published in peer-reviewed scientific journals.”
AstraZeneca/Oxford is racing with Pfizer/BioNTech, Moderna, and others to publish the first detailed results from large COVID-19 vaccine trials.
“We made encouraging headway in the quarter, despite the ongoing disruption from the COVID-19 pandemic,” Chief Executive Officer Pascal Soriot said.
According to the pharmaceutical giant, “Results from late-stage trials are anticipated later this year, depending on the rate of infection within the communities where the clinical trials are being conducted. Data readouts will be submitted to regulators and published in peer-reviewed scientific journals.”
AstraZeneca/Oxford is racing with Pfizer/BioNTech, Moderna, and others to publish the first detailed results from large COVID-19 vaccine trials.
“We made encouraging headway in the quarter, despite the ongoing disruption from the COVID-19 pandemic,” Chief Executive Officer Pascal Soriot said.